GSK boss: Britain must reform drug pricing to become a life sciences superpower
PositiveWorld Affairs

GSK's CEO Emma Walmsley has emphasized the need for Britain to reform its drug pricing system to establish itself as a leader in life sciences. Her comments come as GSK's shares rise due to increased profits, and she expresses optimism about resolving ongoing issues with the NHS regarding medicine costs. This reform is crucial not only for GSK but for the broader UK economy, as it could enhance access to innovative treatments and attract more investment in the life sciences sector.
— Curated by the World Pulse Now AI Editorial System












